Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization

References

• Vandenbroucke JP. When are observational studies as credible as randomised trials?. Lancet. 2004; 363: 1728–31
   PubMed Web of Science ®Google Scholar
• Concato J, Horwitz RI. Beyond randomised versus observational studies. Lancet. 2004; 363: 1660–1
   PubMed Web of Science ®Google Scholar
• Hernán MA, Brumback B, Robins JM. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Statistics in Medicine. 2002; 21: 1689–709
   PubMed Web of Science ®Google Scholar
• Davey Smith G, Ebrahim S. ‘Mendelian Randomisation’: can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol. 2003; 32: 1–22
   PubMed Web of Science ®Google Scholar
• Manson J Stampfer MJ Willett WC Colditz G Rosner B Speizer FE , et al. A prospective study of antioxidant vitamins and incidence of coronary heart disease in women. Circulation. 1991;84 suppl II:II–546.
   Google Scholar
• Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E Consumption and the Risk of Coronary Heart Disease in Men. New Engl J Med. 1993; 328: 1450–6
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E Consumption and the Risk of Coronary Disease in Women. New Engl J Med. 1993; 328: 1444–9
   PubMed Web of Science ®Google Scholar
• Osganian SK, Stampfer MJ, Rimm E, Spiegelman D, Hu FB, Manson JE, et al. Vitamin C and risk of coronary heart disease in women. J Am Coll Cardiol. 2003; 42: 246–52
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47–63 ( reprinted Int J Epidemiol. 2004;33:445–53).
   PubMed Web of Science ®Google Scholar
• Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996; 334: 1150–5
   PubMed Web of Science ®Google Scholar
• The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330:1029–35.
   PubMedGoogle Scholar
• Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354:447–55.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23–33.
   PubMed Web of Science ®Google Scholar
• Beral V, Banks E, Reeves G. Evidence from randomized trials of the long-term effects of hormone replacement therapy. Lancet. 2002; 360: 942–4
   PubMed Web of Science ®Google Scholar
• Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Internal Med. 2004; 164: 1552–6
   PubMed Web of Science ®Google Scholar
• Khaw K-T, Bingham S, Welch A, Luben R, Wareham N, Oakes S, et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. Lancet. 2001; 357: 657–63
   PubMed Web of Science ®Google Scholar
• Lawlor DA, Davey Smith G, Kundu D, Bruckdorfer KR, Ebrahim S. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?. Lancet. 2004; 363: 1724–7
   PubMed Web of Science ®Google Scholar
• Lawlor DA, Ebrahim S, Kundu D, Bruckdorfer KR, Whincup PH, Davey Smith G. Vitamin C is not associated with coronary heart disease risk once life course socioeconomic position is taken into account: Prospective findings from the British Women's Heart and Health Study. Heart. 2005; 91: 1086–7
   Google Scholar
• Spearman C. The proof and measurement of association between two things. Am J Psychol. 1904; 15: 72–101
   Web of Science ®Google Scholar
• Davey Smith G, Phillips AN. Inflation in epidemiology: ‘The proof and measurement of association between two things’ revisited. Br Med J. 1996; 312: 1659–61
   Google Scholar
• Peto R. Two properties of multiple regression analysis and regression to the mean (and regression from the mean). The natural history of chronic bronchitis and emphysema: an eight year study of early chronic obstructive lung disease in working men in London, CM Fletcher, R Peto, CM Tinker, FE Speizer. Oxford University Press, Oxford 1976; 218–23
   Google Scholar
• Davey Smith G, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004; 33: 30–42
   PubMed Web of Science ®Google Scholar
• Davey Smith G, Ebrahim S. What can mendelian randomization tell us about modifiable behavioural and environmental exposures. BMJ. 2005; 330: 1076–9
   Google Scholar
• Davey Smith G. Randomised by (your) god: robust inference from an observational study design. J Epidemiol Community Health. 2006; 60: 382–8
   Google Scholar
• Davey Smith G, Ebrahim S. Mendelian randomization: Genetic variants as instruments for strengthening causal inference in observational studies. Biosocial surveys: Current insight and future promise. National Research Council, JW Vaupel, M Weinstein, KW Wachter. The National Academies Press, Washington, DC 2008; 336–66
   Google Scholar
• Goldschmidt RB. Physiological Genetics. McGraw Hill, New York 1938
   Google Scholar
• Baron DN, Dent CE, Harris H, Hart EW, Jepson JB. Hereditary pellagra-like skin rash with temporary cerebellar ataxia, constant renal amino-aciduria, and other bizarre biochemical features. Lancet. 1956; 271: 421–8
   Google Scholar
• Snyder LH. Fifty years of medical genetics. Science. 1959; 129: 7–13
   Google Scholar
• Guy JT. Oral manifestations of systematic disease. Otolaryngology—Head and Neck Surgery, CW Cummings. Mosby Year Book, Inc, St Louis 1993; 2
   Google Scholar
• Gause GF. The relation of adaptability to adaption. Q Rev Biol. 1942; 17: 99–114
   Google Scholar
• Jablonka-Tavory E. Genocopies and the evolution of interdependence. Evolutionary Theory. 1982; 6: 167–70
   Google Scholar
• Palmer L, Cardon L. Shaking the tree: mapping complex disease genes with linkage disequilibrium. Lancet. 2005; 366: 1223–34
   PubMed Web of Science ®Google Scholar
• Keavney B, Danesh J, Parish S, Palmer A, Clark S, Youngman L, et al. Fibrinogen and coronary heart disease: test of causality by ‘Mendelian randomization’. Int J Epidemiol. 2006; 35: 935–43
   PubMed Web of Science ®Google Scholar
• Bhatti P, Sigurdson AJ, Wang SS, Chen J, Rothman N, Hartge P, et al. Genetic variation and willingness to participate in epidemiological research: data from three studies. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2449–53
   Google Scholar
• Marmot M. Reflections on alcohol and coronary heart disease. Int J Epidemiol. 2001; 30: 729–34
   Google Scholar
• Bovet P, Paccaud F. Alcohol, coronary heart disease and public health: which evidence-based policy?. Int J Epidemiol. 2001; 30: 734–7
   Google Scholar
• Klatsky AL. Commentary: Could abstinence from alcohol be hazardous to your health?. Int J Epidemiol. 2001; 30: 739–42
   Google Scholar
• Shaper AG. Editorial: alcohol, the heart, and health. Am J Public Health. 1993; 83: 799–801
   PubMed Web of Science ®Google Scholar
• Hart C, Davey Smith G, Hole D, Hawthorne V. Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: results from a prospective cohort study of Scottish men with 21 years of follow up. BMJ. 1999; 318: 1725–9
   PubMed Web of Science ®Google Scholar
• Rimm E. Commentary: Alcohol and coronary heart disease—laying the foundation for future work. Int J Epidemiol. 2001; 30: 738–9
   Google Scholar
• Enomoto N, Takase S, Yasuhara M, Takada A. Acetaldehyde metabolism in different aldehyde dehydrogenase-2 genotypes. Alcohol Clin Exp Res. 1991; 15: 141–4
   PubMed Web of Science ®Google Scholar
• Takagi S, Iwai N, Yamauchi R, Kojima S, Yasuno S, Baba T, et al. Aldehyde dehydrogenase 2 gene is a risk factor for myocardial infarction in Japanese Men. Hypertens Res. 2002; 25: 677–81
   PubMed Web of Science ®Google Scholar
• Chao Y-C, Liou S-R, Chung Y-Y, Tang H-S, Hsu C-T, Li T-K, et al. Polymorphism of alcohol and aldehyde dehydrogenase genes and alcoholic cirrhosis in Chinese patients. Hepatology. 1994; 19: 360–6
   PubMed Web of Science ®Google Scholar
• Burr ML, Fehily AM, Butland BK, Bolton CH, Eastham RD. Alcohol and high-density-lipoprotein cholesterol: a randomized controlled trial. Br J Nutr. 1986; 56: 81–6
   PubMed Web of Science ®Google Scholar
• Chen L, Davey Smith G, Harbord R, Lewis S. Alcohol intake and blood pressure: a systematic review implementing a Mendelian Randomization approach. PLoS Medicine 2008; 5: 461–471
   Google Scholar
• LDL receptor mutation catalogue. Available at: http://www.ucl.ac.uk/fh (accessed 16 December 2003).
   Google Scholar
• Marks D, Thorogood M, Neil HAW, Humphries SE. A review on diagnosis, natural history and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003; 168: 1–14
   PubMed Web of Science ®Google Scholar
• Slack J. Risks of ischaemic heart disease in familial hyperlipoproteinaemic states. Lancet. 1969; 2: 1380–2
   PubMed Web of Science ®Google Scholar
• Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ. 1991;303:893–6.
   PubMedGoogle Scholar
• Cholesterol sceptics website. Available at: http://www.thincs.org/ (accessed 16 August 2007).
   Google Scholar
• Steinberg D. Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy. Part 1. J Lipid Res. 2004; 45: 1583–93
   PubMed Web of Science ®Google Scholar
• Steinberg D. Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy. Part II. The early evidence linking hypercholestrolemia to coronary disease in humans. J Lipid Res. 2005; 46: 179–90
   PubMed Web of Science ®Google Scholar
• Færgeman O. Coronary Artery Disease: Genes Drugs and the Agricultural Connection. Elsevier, AmsterdamNetherlands 2003
   Google Scholar
• Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Lowering Treatments Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267–78
   PubMed Web of Science ®Google Scholar
• Rose G. Incubation period of coronary heart disease. BMJ. 1982; 284: 1600–1
   PubMedGoogle Scholar
• Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci U S A. 1989; 86: 587–91
   PubMed Web of Science ®Google Scholar
• Tybjaerg-Hansen A, Humphries SE. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease. Atherosclerosis. 1992; 96: 91–107
   PubMed Web of Science ®Google Scholar
• Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 1993; 104: 1–18
   Google Scholar
• Tybjærg-Hansen A, Steffenson R, Meinertz H, Schnohr P, Nordestgaard BG. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. New Engl J Med. 1998; 338: 1577–84
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosely TH, Hobbs HH. Sequence variations in PSCK9, low LDL, and protection against coronary heart disease. New Eng J Med. 2006; 354: 1264–72
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. Lowering LDL—not only how low, but how long?. Science. 2006; 311: 1721–3
   PubMed Web of Science ®Google Scholar
• Danesh J, Wheller JB, Hirschfield GM, Eda S, Eriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation. In the prediction of coronary heart disease. New Engl J Med. 2004; 350: 1387–97
   PubMed Web of Science ®Google Scholar
• Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 2002; 155: 65–71
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286: 327–34
   PubMed Web of Science ®Google Scholar
• Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002; 25: 2016–21
   PubMed Web of Science ®Google Scholar
• Sesso D, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003; 290: 2945–51
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM. 2003; 9: 793–807
   Google Scholar
• Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women. Diabetes. 2004; 53: 693–700
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. New Engl J Med. 2005; 352: 20–8
   PubMed Web of Science ®Google Scholar
• Sjöholm A, Nyström T. Endothelial inflammation in insulin resistance. Lancet. 2005; 365: 610–2
   PubMed Web of Science ®Google Scholar
• Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med. 2005; 2: 29–36
   PubMedGoogle Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557–65
   PubMed Web of Science ®Google Scholar
• Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000; 321: 199–204
   PubMed Web of Science ®Google Scholar
• Ridker P. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet. 2001; 358: 946–8
   PubMed Web of Science ®Google Scholar
• Taylor KE, Giddings JC, van den Berg CW. C-Reactive protein induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol. 2005; 25: 1225–30
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2005; 102: 8309–14
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006; 440: 1217–21
   PubMed Web of Science ®Google Scholar
• Davey Smith G, Lawlor D, Harbord R, Timpson N, Rumley A, Lowe G, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and Mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol. 2005; 25: 1051–6
   PubMed Web of Science ®Google Scholar
• Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day INM, Palmer LJ, et al. C-reactive protein and its role in metabolic syndrome: mendelian randomization study. Lancet. 2005; 366: 1954–9
   PubMed Web of Science ®Google Scholar
• Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, Gaffney D, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol. 2006; 35: 922–31
   PubMed Web of Science ®Google Scholar
• Davey Smith G, Harbord R, Milton J, Ebrahim S, Sterne JAC. Does Elevated Plasma Fibrinogen Increase the Risk of Coronary Heart Disease? Evidence from a Meta-Analysis of Genetic Association Studies. Arterioscler Thromb Vasc Biol. 2005; 25: 2228–33
   Google Scholar
• Tegner J, Bjorkegren J. Perturbations to uncover gene networks. Trends Genet. 2007; 23: 34–41
   PubMed Web of Science ®Google Scholar
• Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ. 2000; 321: 208–13
   PubMedGoogle Scholar
• Sung J, Song Y-M, Choi Y-H, Ebrahim S, Davey Smith G. Hepatitis B Virus Seropositivity and the Risk of Stroke and Myocardial Infarction. Stroke. 2007; 38: 1436
   Google Scholar
• Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA. 2005; 293: 2641–7
   PubMed Web of Science ®Google Scholar
• Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004; 351: 2611–18
   PubMed Web of Science ®Google Scholar
• Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002; 347: 185–92
   PubMed Web of Science ®Google Scholar
• Smeeth L, Casas JP, Hingorani AD. The role of infection in cardiovascular disease: more support but many questions remain. Eur Heart J. 2007; 28: 1178–9
   Google Scholar
• Jousilahti P, Salomaa V. Fibrinogen, social position, and Mendelian randomisation. J Epidemiol Community Health. 2004; 58: 883
   Google Scholar
• Glynn RK. Commentary: Genes as instruments for evaluation of markers and causes. Int J Epidemiol. 2006; 35: 932–4
   Google Scholar
• Thomas DC, Conti DV. Commentary on the concept of ‘Mendelian Randomization’. Int J Epidemiol. 2004; 33: 17–21
   Google Scholar
• Didelez V Sheehan NA Mendelian randomization: Why Epidemiology needs a formal language for causality. Stat Methods Med Res. 2007 ( in press).
   Google Scholar
• Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008; 27: 1133–63
   PubMed Web of Science ®Google Scholar
• Colhoun H, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003; 361: 865–72
   PubMed Web of Science ®Google Scholar
• Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–78.
   PubMed Web of Science ®Google Scholar
• Frayling T, Timpson NJ, Weedon N, Zeggini E, Freathy RM, Lindgren CM. A Common Variant in the FTO Gene Is Associated with Body Mass Index and Predisposes to Childhood and Adult Obesity. Science. 2007; 316: 889–94
   PubMed Web of Science ®Google Scholar
• Waddington CH. Canalization of development and the inheritance of acquired characteristics. Nature. 1942; 150: 563–5
   Google Scholar
• Wilkins AS. Canalization: a molecular genetic perspective. Bioessays. 1997; 19: 257–62
   Google Scholar
• Rutherford SL. From genotype to phenotype: buffering mechanisms and the storage of genetic information. BioEssays. 2000; 22: 1095–105
   PubMedGoogle Scholar
• Gibson G, Wagner G. Canalisation in evolutionary genetics: a stabilising theory?. BioEssays. 2000; 22: 372–80
   PubMedGoogle Scholar
• Hartman JLT, Garvik B, Hartwell L. Principles for the buffering of genetic variation. Science. 2001; 291: 1001–4
   PubMed Web of Science ®Google Scholar
• Debat V, David P. Mendelian randomization as an instrumental variable approach to caausal inference. Trends Ecol Evol. 2001; 16: 555–61
   Web of Science ®Google Scholar
• Kitami T, Nadeau JH. Biochemical networking contributes more to genetic buffering in human and mouse metabolic pathways than does gene duplication. [erratum appears in Nat Genet. 2002;32:681]. Nat Genet. 2002; 32: 191–4
   Google Scholar
• Gu Z, Steinmetz LM, Gu X, Scharfe C, Davis RW, Li W-H. Role of duplicate genes in genetic robustness against null mutations. Nature. 2003; 421: 63–6
   PubMed Web of Science ®Google Scholar
• Hornstein E, Shomron N. Canalization of development by microRNAs. Nat Genet. 2006; 38: S20–4
   PubMed Web of Science ®Google Scholar
• Davey Smith G, Lawlor DA, Harbord R, Timpson NJ, Day I, Ebrahim S. Clustered Environments and Randomized Genes: a fundamental distinction between conventional and genetic epidemiology. PLoS-Med. 2007; 4: e352
   PubMed Web of Science ®Google Scholar
• Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008; 358;12: 1240–1249
   Google Scholar
• Juul K, Tybjaerg-Hansen A, Marklund S, Heegaard NHH, Steffensen R, Sillesen H, et al. Genetically reduced antioxidative protection and increased ischaemic heart disease risk: the Copenhagen city heart study. Circulation. 2004; 109: 59–65
   PubMed Web of Science ®Google Scholar
• Weiss K, Terwilliger J. How many diseases does it take to map a gene with SNPs?. Nat Genet. 2000; 26: 151–7
   PubMed Web of Science ®Google Scholar
• Langlois MR, Delanghe JR, De Buyzere ML, Bernard DR. Ouyang J. Effect of haptoglobin on the metabolism of vitamin C. Am J Clin Nutr. 1997; 66: 606–10
   PubMed Web of Science ®Google Scholar
• Delanghe J, Langlois M, Duprez D, De Buyzere M, Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis. 1999; 145: 287–92
   PubMed Web of Science ®Google Scholar
• Erichsen HC, Eck P, Levine M, Chanock S. Characterization of the genomic structure of the human vitamin C transporter SVCT1 (SLC23A2). J Nutr. 2001; 131: 2623–7
   PubMedGoogle Scholar
• Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet. 2001; 2: 91–9
   PubMed Web of Science ®Google Scholar